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Abstract
Background: Catalase is an important antioxidant enzyme that regulates the level of intracellular hydrogen
peroxide and hydroxyl radicals. The effects of catalase deficiency on albuminuria and progressive glomerulosclerosis
have not yet been fully elucidated. The adriamycin (ADR) nephropathy model is considered to be an experimental
model of focal segmental glomerulosclerosis. A functional catalase deficiency was hypothesized to exacerbate
albuminuria and the progression of glomerulosclerosis in this model.
Methods: ADR was intravenously administered to both homozygous acatalasemic mutant mice (C3H/AnLCs
bCs
b)
and control wild-type mice (C3H/AnLCs
aCs
a). The functional and morphological alterations of the kidneys, including
albuminuria, renal function, podocytic, glomerular and tubulointerstitial injuries, and the activities of catalase were
then compared between the two groups up to 8 weeks after disease induction. Moreover, the presence of a
mutation of the toll-like receptor 4 (tlr4) gene, which was previously reported in the C3H/HeJ strain, was
investigated in both groups.
Results: The ADR-treated mice developed significant albuminuria and glomerulosclerosis, and the degree of these
conditions in the ADR-treated acatalasemic mice was higher than that in the wild-type mice. ADR induced
progressive renal fibrosis, renal atrophy and lipid peroxide accumulation only in the acatalasemic mice. In addition,
the level of catalase activity was significantly lower in the kidneys of the acatalasemic mice than in the wild-type
mice during the experimental period. The catalase activity increased after ADR injection in wild-type mice, but the
acatalasemic mice did not have the ability to increase their catalase activity under oxidative stress. The C3H/AnL
strain was found to be negative for the tlr4 gene mutation.
Conclusions: These data indicate that catalase deficiency plays an important role in the progression of renal injury
in the ADR nephropathy model.
Background
The degree of oxidative stress and the severity of subse-
quent tissue injury may depend on an imbalance
between the excessive production of reactive oxygen
species and the antioxidant defense. The antioxidants
include the enzymes superoxide dismutase (SOD), cata-
lase, and glutathione peroxidase (GPX), which detoxify
reactive oxygen species. Catalase (E.C.1.11.1.6) is a
major enzyme that catalyzes the decomposition of
hydrogen peroxide (H2O2) and plays a role in cellular
antioxidant defense mechanisms [1]. The main reaction
of catalase is the catalytic reaction (2H2O2 ® O2+
2H2O), which is essential for the removal of excessive
H2O2 and for regulating the H2O2 concentration [2].
Catalase limits the accumulation of H2O2 generated by
v a r i o u so x i d a s e si nt i s s u e ,a n ds e r v e sa sas u b s t r a t ef o r
the Fenton reaction to produce the highly injurious
hydroxyl radicals. Genetic defects of catalase were first
documented by Takahara [3] in Japanese patients who
exhibited a deficiency of blood catalase enzyme activity
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mouse strain (Cs
b) was established by Feinstein, Suter,
and Jaroslow [6] from the progeny of x-ray-irradiated
mice.
Focal segmental glomerulosclerosis (FSGS) is a common
cause of nephrotic syndrome in both children and adults
[7,8]. The clinicopathological syndrome may be classified
as primary, secondary or familial. The primary defect in
FSGS lies in the filtration barrier of the glomeruli. Disrup-
tion of the filtration barrier results in the loss of perms-
electivity, and macromolecules such as albumin are
allowed to enter the urine. Chen et al. [9] reported that
BALB/c mice were susceptible to renal toxicity arising
from the administration of the anthracycline antibiotic,
adriamycin (ADR), with selective injury to podocytes
resulting in severe proteinuria and progressive renal failure
[9,10]. This was described as the first experimental model
of FSGS in mice. The activities of antioxidant enzymes
including catalase, GPX and Mn-SOD and the glutathione
concentration in renal cortex were decreased by ADR
n e p h r o p a t h yi nB A L B / cm i c e[ 1 1 ] .T h el e v e lo fn i t r i c
oxide in kidney homogenates [12], and the urinary levels
of nitrite/nitrate [10] were also increased in the ADR
nephropathy model. The administration of the soluble
receptor for advanced glycation endproducts (AGEs) sup-
pressed AGE generation and reactive oxygen species in
the ADR nephropathy mice [13].
In the present study, we hypothesized that a defect in
the antioxidant system in the form of catalase deficiency
would enhance proteinuria, glomerular sclerosis, and
eventually lead to the loss of renal function. This
hypothesis was tested using the ADR nephropathy
model, which is a well-established model of progressive
FSGS, in acatalasemic mice.
Methods
Experimental animal protocol
Male wild-type mice (C3H/AnLCs
aCs
a) and male homozy-
gous acatalasemic mutant mice (C3H/AnLCs
bCs
b)w e r e
used at the age of 8 - 10 weeks. Animals were housed in
cages and fed standard chow and water ad libitum.A D R
(10, 15 and 20 mg/kg BW) dissolved in saline was intrave-
nously administered to both acatalasemic mutant mice and
control wild-type mice [14]. In the C3H/AnL strain, the
dose of 10 mg/kg BW did not induce significant albumi-
nuria or increase mortality (Additional file 1: Figure S1A).
The 20 mg/kg BW dose resulted in a rapid increase in
mortality in both groups of mice (Additional file 1: Figure
S1C). The ADR-induced cardiotoxicity might have led to
the high mortality resulting from the higher dose of ADR
[15]. A total of 55.3% of the acatalasemic mice and 59.2%
of the wild-type mice survived 8 weeks after the injection
of 15 mg/kg BW ADR (Additional file 1: Figure S1B) with
a substantial amount of albuminuria. Therefore, 15 mg/kg
BW ADR was considered to be a suitable concentration to
investigate the effects of a functional catalase deficiency in
the ADR nephropathy model. In the control mice, the
same volume of saline was injected intravenously.
Mice were divided into subgroups (n = 6-15/group).
Their body weight was measured at 0, 4 and 8 weeks.
The mice were sacrificed at 0, 4 and 8 weeks after ADR
administration, then their kidneys and hearts were har-
vested, washed with saline, blotted dry on gauze, and
weighed as described previously [16,17]. The whole kid-
n e yw e i g h ta n dh e a r tw e i g h tw e r ee x p r e s s e da sap e r -
centage of the body weight determined at the time the
mice were sacrificed. Twenty-four hour urine samples
were collected in metabolic cages every 4 weeks. Imme-
diately before death, blood samples were drawn. The
serum creatinine, blood urea nitrogen (BUN), and urin-
ary albumin excretion (UAE) levels were measured, and
the creatinine clearance (Ccr) was calculated as
described previously [16]. The experimental protocol
was approved by the Ethics Review Committees for Ani-
mal Experimentation of Okayama University Graduate
School (OKU-2009226).
Reagents and antibodies
Chemicals and reagents of analytical grade were pur-
chased from Sigma Co. Ltd. (St. Louis, Missouri) or
Wako Pure Chemical Ind. (Osaka, Japan) unless stated
otherwise. The mouse monoclonal antibody to 4-
hydroxy-2-nonenal (4-HNE) was obtained from Nof Life
Science (Tokyo, Japan). The N-histofine MOUSESTAIN
KIT was obtained from NICHIREI BIOSCIENCES INC.
(Tokyo, Japan). The catalase assay kit was obtained from
Cayman (Ann Arbor, Michigan).
Light and electron microscopic studies
The kidneys were removed, fixed in 10% buffered for-
malin, and embedded in paraffin. Paraffin sections (3-
μm thick) were stained with periodic acid-Schiff (PAS)
and Masson’s trichrome stain. Each tissue section was
evaluated under an Olympus light microscope (Olym-
pus, Tokyo, Japan) with a high-resolution digital camera
system (Penguin 600CL; Pixera Co., Los Gatos, CA).
The area of glomeruli was measured using a Microana-
lyzer software program (version 1.1, Japan Poladigital
Co., Tokyo, Japan) [18]. Glomerulosclerosis was quanti-
fied using the percentage increase in the relative mesan-
gial matrix area (the PAS-positive area within the
glomerulus divided by the glomerular capillary area;
high magnification). All mean values were calculated
from 10 glomeruli. Electron microscopy was performed
for the mouse kidney specimens as described previously
[16,17]. A quantitative analysis was performed to count
the number of podocyte foot processes per 10 μmo f
glomerular basement membrane in each glomerulus by
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foot processes was defined as the effacement score. The
area of interstitial fibrosis in the cortex was evaluated
with Masson’s trichrome as described previously [19],
with some modifications. Under low magnification, the
number of casts in five randomly selected non-overlap-
ping fields from the cortical region was counted and
averaged as the cast score.
Immunohistochemistry
To detect lipid oxidation products, paraffin sections (3-
μmt h i c k )w e r es t a i n e du s i n ga nN - h i s t o f i n eM O U S E S -
TAIN KIT as described previously [20]. A mouse
monoclonal antibody to 4-HNE was used as the primary
antibody (1:100 dilution). Under low magnification, five
randomly selected non-overlapping fields from the cor-
tical region were analyzed. The 4-HNE positive areas
that were stained in brown were picked up on digital
images, and the percentage of the 4-HNE positive area
relative to the whole area of the field was calculated (%
area).
Renal catalase activity
Kidney samples were stored in a -80°C freezer until
being assayed. The catalase activity in each kidney was
determined by an ELISA using a catalase assay kit [21].
All procedures were performed according to the manu-
facturer’s instructions.
Toll-like receptor-4 gene (Tlr4) mutation analysis in exon
3 in wild-type (C3H/AnLCs
aCs
a) and acatalasemic mice
(C3H/AnLCs
bCs
b)
The detection of the Tlr4 mutation was performed using
nested-PCR as described previously [22]. The nested
PCR for detection of the missense mutation, a C to A
transversion (Pro712His), which was reported in the
C3H/HeJ mouse strain [23], was performed using the
primers shown in Additional file 2: Table S1. The pri-
mers TLR4-ex3-F and TLR4-ex3-R were used for direct
sequencing of DNA extracted from the mouse kidneys.
Statistical analyses
The data were shown as the means ± SE. The normal
distribution and homogeneity of variance were checked,
and logarithmic transformations were made for the vari-
ables if needed. Multiple comparisons between groups
were made by Scheffe’s test or the Steel-Dwass test. A
Kaplan-Meier analysis and the Log-Rank statistic were
used to explore the effects of ADR in both groups of
mice. The statistical analysis was performed using the
Excel add-in software Statcel 2 program (OMS, Tokyo,
Japan) or the JMP 9 software program (SAS Institute
Inc., Cary, North Carolina). P < 0.05 denoted the pre-
sence of a statistically significant difference.
Results
Changes in body weight, kidney weight, and heart weight
in the mouse ADR nephropathy model
The ADR nephropathy model has been extensively stu-
died in animals of the BALB/c background. Therefore,
we first tried to characterize this model in our mouse
strains. The body weight, relative kidney weight and
relative heart weight were similar between the groups at
the start of the experiment (Table 1). Both groups of
mice lost a similar amount of body weight by 8 weeks
after ADR administration. However, the relative kidney
weight in acatalasemic mice was lower at 8 weeks than
that in wild-type mice after ADR administration. The
relative heart weights were similar for both groups dur-
ing the experimental period.
The increase in albuminuria is significantly accelerated in
acatalasemic mice after ADR administration
To evaluate the effect of acatalasemia on ADR-induced
alterations of biological functions, we measured the
parameters of renal function (Table 1) and UAE (Figure
1). The basal levels of BUN and Ccr were not signifi-
cantly different between the wild-type and acatalasemic
mice. In both groups, the renal function did not signifi-
cantly change during the experimental period. However,
UAE was elevated significantly after ADR administration
at weeks 4 and 8 in both groups. The UAE in the acata-
lasemic mice was higher than that in wild-type mice
after ADR administration at week 4.
Table 1 The metabolic and laboratory data of the mice
Group 0 week 4 week 8 week
Body weight (g)
Wild ADR 29.1 ± 0.50 29.6 ± 0.41 24.8 ± 0.97
a, c
Acatalasemic ADR 28.0 ± 0.40 28.2 ± 0.31 24.1 ± 0.84
b, d
Relative kidney weight (% of body wt)
Wild ADR 1.68 ± 0.05 1.67 ± 0.04 1.70 ± 0.13
Acatalasemic ADR 1.94 ± 0.04 1.66 ± 0.04 1.30 ± 0.08
b, c, e
Relative heart weight (% of body wt)
Wild ADR 0.38 ± 0.02 0.48 ± 0.02 0.48 ± 0.05
Acatalasemic ADR 0.43 ± 0.03 0.52 ± 0.01 0.40 ± 0.03
Blood urea nitrogen (mg/dl)
Wild ADR 23.8 ± 1.29 26.4 ± 0.77 25.6 ± 4.31
Acatalasemic ADR 26.0 ± 1.02 26.7 ± 2.56 32.6 ± 4.16
Creatinine clearance (μl/min/g BW)
Wild ADR 2.68 ± 0.81 3.80 ± 0.99 2.10 ± 0.77
Acatalasemic ADR 3.53 ± 1.27 3.21 ± 1.13 1.61 ± 0.61
The values are the means ± SE of 6 to 43 animals in each group
Wild, wild-type mice; Acatalasemic, acatalasemic mice; ADR, adriamycin
a P < 0.05 vs. week 0 in the same group
b P < 0.01 vs. week 0 in the same group
c P < 0.05 vs. week 4 in the same group
d P < 0.01 vs. week 4 in the same group
e P < 0.01 vs. the wild-type ADR group at the same time point
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tubulointerstitial fibrosis
At the start of the experiment, no histological abnormal-
ities of the glomeruli were observed at the light micro-
scopic level in either group (Figure 2A and 2B). The
glomeruli in the acatalasemic mice were significantly
hypertrophied after ADR administration at week 4 (Fig-
ure 2D and 2G). In the acatalasemic mice, glomerulo-
sclerosis developed earlier than in wild-type mice, and it
was significantly increased at week 4 compared with
that in wild-type mice after ADR administration (Figure
2C through F and 2H). A decrease in the effacement
score of the podocyte foot processes was observed in
glomeruli of both groups of mice (Additional file 3: Fig-
ure S2A through F), however, there were no significant
changes in the effacement scores in either group at
week 4 and 8 after ADR administration (Additional file
3: Figure S2G). Tubulointerstitial fibrosis developed sig-
nificantly in the kidneys of acatalasemic mice group
( F i g u r e3 B ,D ,Fa n d3 G )a t4a n d8w e e k sa f t e rA D R
administration, with significant cast formation noted at
week 4 (Figure 3H). The tubulointerstitial changes in
the kidneys of wild-type mice after ADR administration
were not statistically significant compared to that of aca-
talasemic mice (Figure 3A, C, E, G and 3H).
Acatalasemia enhances the accumulation of lipid
peroxides in the kidneys of the ADR nephropathy model
mice
Modification of proteins and lipids by oxidative stress is
believed to play a central role in a variety of biological
activities, such as apoptosis and extracellular matrix
expansion [18,24,25]. The major content of the cell
membrane is lipids, and thus, lipid peroxidation may
cause renal injury. We next examined whether acatalase-
mia influenced the lipid peroxidation products in the
tubulointerstitial compartment of the kidneys in ADR
nephropathy. At the start of the experiment, there was
almost no accumulation of 4-HNE in the kidneys of
either group (Figure 4A and 4B). There was an increase
in the 4-HNE antibody labeling of various patches in
the tubules of kidneys after ADR administration in both
groups (Figure 4C through 4F). The degree of 4-HNE
accumulation in the cortex of the kidneys in acatalase-
mic mice was significantly higher than that in wild-type
mice 8 weeks after ADR administration (Figure 4G).
The catalase activity in acatalasemic ADR nephropathy
kidneys did not significantly change
The maintenance of tissue homeostasis requires an
appropriate balance between oxidants and antioxidants.
Two major antioxidant enzymes, catalase and GPX, are
physiologically involved in the detoxification of H2O2,
and thus protect tissues from oxidant-mediated injury.
Therefore, we next examined the catalase activity in aca-
talasemic ADR kidneys. Although the renal catalase
activity of the wild-type mice was increased significantly
at week 4 after ADR administration, that from the acata-
lasemic mice was decreased compared with wild-type
mice at the start of the experiment, and remained low
during the entire experimental period (Figure 5). Since
high catalase levels are found in erythrocytes, we com-
pared the catalase activity between saline-perfused and
unperfused kidneys after the removal of residual blood.
The catalase activity of the perfused kidney was 6.0 ±
0.2% lower than that of the unperfused kidney [17]. Since
the catalase activity was enhanced in wild-type mice 4
weeks after ADR administration and was thought to con-
tribute to reactive oxygen elimination, we investigated
the levels of other renal antioxidant enzymes, such as
G P Xa n dS O D ,i nw i l d - t y p eo ra c a t a l a s e m i cm i c e4
weeks after ADR administration. The activity levels of
GPX and SOD did not show any remarkable changes in
either of the groups of mice (data not shown). Since SOD
catalyzes the conversion of the superoxide anion radical
to H2O2 and O2, it has been suggested that the level of
production of ROS mediated by SOD may be similar in
the ADR-nephropathy kidneys in both groups.
Toll-like receptor-4 mutation analysis
To examine the background of the mouse strains, we
performed a mutation analysis of Tlr4 exon 3. Tlr4 did
not show a C to A transversion due to a missense muta-
tion in the C3H/AnL mouse strain, which was reported
to be present in the C3H/HeJ strain (Additional file 4:
Figure S3) [23].
Figure 1 The changes in urinary albumin excretion (UAE) in
wild-type (open bars) and acatalasemic mice (closed bars). The
UAE significantly increased in both groups at 4 and 8 weeks after
Adriamycin (ADR) administration. The elevation of UAE in
acatalasemic mice was higher at 4 weeks after ADR administration
compared to that in wild-type mice. Each column consists of the
means ± SE. N = 9 to 39 animals/group. **: P < 0.01 vs. wild-type
ADR mice at the same time point. #: p < 0.05 vs. week 0 in the
same group. ##: p < 0.01 vs. week 0 in the same group.
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In the present study, acatalasemic mouse strains defi-
cient in catalase activity were used as an animal model.
T h e s em i c ew e r ef o u n dt ob em o r es u s c e p t i b l et of u n c -
tional and morphological alterations in the kidneys
induced by adriamycin than wild-type mice. The level of
albuminuria and glomerulosclerosis in the acatalasemic
mice after adriamycin injection was significantly higher
than that in the wild-type mice. The renal catalase activ-
ity in these mice remained low, without compensatory
Figure 2 The renal histology in wild-type and acatalasemic mice. Light micrographs of a glomerulus of wild-type (A, C and E)a n d
acatalasemic (B, D and F) glomeruli at 0, 4 and 8 weeks after adriamycin (ADR) administration are shown. The week 0 glomeruli were
microscopically normal. Note that the segmental sclerosis is significant in both acatalasemic and wild-type glomeruli at the later time points. The
glomerular area (G) and sclerosis index (H) of wild-type (open bars) or acatalasemic (closed bars) mice are also shown. A through F: periodic
acid-Schiff stain. Scale bars: 20 μm( A through F). G and H: Each column shows the means ± SE. N = 6 to 15 animals/group. *: P < 0.05 vs. wild-
type ADR mice at the same time point. #: p < 0.05 vs. week 0 in the same group. ##: p < 0.01 vs. week 0 in the same group.
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suggest that the increased ROS, particularly the hydroxyl
radical, resulting from the reduction of catalase activity,
may be involved in the acceleration of glomerulosclero-
sis found under acatalasemic disease conditions.
Although some rat strains show complete suscept-
ibility to ADR, most mouse strains do not. Zheng et al.
showed that AKR/J, C3H/HeJ, CBA/J, C57BL/10J, LP/J,
SWR/J, SJL/J, and 129S6/SvEvTac mice were resistant
to ADR nephropathy, whereas 129S1/SvImJ and BALB/
cByJ mice were susceptible [26,27]. They also showed
that the susceptible allele for the adriamycin was
present in the DOXNPH locus [28]. We did not con-
firm whether this allele is present in the C3H/AnL
mouse strain. Instead, we performed a mutation analy-
sis of the TLR4 gene, because it has been thought that
TLR4 is involved in progressive renal fibrosis [29].
TLR4 is considered to be the critical component of the
LPS receptor complex. In 1998, a point mutation in
the TLR4 gene was found to be the molecular basis of
the LPS hyporesponsiveness in C3H/HeJ mice [23].
T h eC 3 H / A n Lm i c eu s e di nt h ep r e s e n ts t u d yd i dn o t
have this mutation. Therefore, ADR induced mild
renal fibrosis in both groups, although the degree of
Figure 3 Light micrographs of the wild-type (A, C and E) and acatalasemic (B, D and F) kidney cortex at 0, 4 and 8 weeks after
adriamycin (ADR) administration are shown. Note that interstitial fibrosis significantly developed in the kidneys of the acatalasemic mice. The
fibrosis scores (G) and cast scores (H) of wild-type (open bars) and acatalasemic (closed bars) mice are also shown. A through F: Masson’s
trichrome stain. Scale bars: 200 μm( A through F). G and H: Each column includes the means ± SE. N = 6 to 15 animals/group. #: p < 0.05 vs.
week 0 in the same group. ##: p < 0.01 vs. week 0 in the same group.
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Page 6 of 10Figure 4 Immunohistochemical staining of 4-hydroxy-2-nonenal (4-HNE).W i l d - t y p e( A, C and E) and acatalasemic (B, D and F)c o r t e x
samples at 0, 4 and 8 weeks after adriamycin (ADR) administration are shown. The 4-HNE positive areas (G) of wild-type (open bars) or
acatalasemic (closed bars) mice are also shown. Scale bars: 50 μm( A through F). G: Each column shows the means ± SE. N = 6 to 8 animals/
group. **: P < 0.01 vs. wild-type ADR mice at the same time point. ##: p < 0.01 vs. week 0 in the same group.
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mic mice.
ADR induced severe albuminuria, thus leading to
values ranging from 23 to 226 mg/mgCr in BALB/cj
mice and a value of 0.04 mg/gCr in B6/D2 mice [30]. In
our study, ADR induced relatively mild albuminuria,
with 0.6 mg/mgCr in wild-type and 1.5 mg/mgCr in
acatalasemic mice. The C3H/AnL mouse strain is con-
sidered to have mild sensitivity to ADR. A single dose of
ADR (9.5 mg/kg BW) brought about 40% segmental glo-
m e r u l o s c l e r o s i si nt h eB A L B / cm o u s es t r a i ni nap r e -
vious study [31]. The wild-type mice which we used in
this study had only 15% segmental glomerulosclerosis at
week 8 after administration, while the acatalasemic mice
had 20% glomerulosclerosis at week 8. This indicates
that when the catalase activity is decreased, the resis-
tance to ADR is diminished, and segmental glomerulo-
sclerosis is induced. The number of foot processes of
the podocytes did not differ between the mouse groups,
indicating that the foot process effacement of the podo-
cytes was affected to a similar degree in both mouse
groups. The discrepancy between the level of albumi-
nuria and the degree of foot process effacement may be
due to the fact that this evaluation procedure compares
only the surviving podocytes in the unsclerosed
glomerulus.
Noiri et al. previously investigated the percentage of
cortical interstitial volume in the ADR model [19], and
Turnberg et al. evaluated tubulointerstitial injury,
including cast formation [32]. We evaluated the pre-
sence of tubulointerstitial injury in similar analyses, and
found significant tubulointerstitial injury only in the aca-
talasemic mice. The fact that acatalasemia exacerbates
pulmonary fibrosis in bleomycin-induced lung injury
[33] and chlorhexidine gluconate-induced peritoneal
fibrosis [34] was already demonstrated. In this study, we
showed that acatalasemia exacerbates renal fibrosis in a
murine FSGS model.
The overexpression of catalase prevented albumi-
nuria and interstitial fibrosis in the angiotensinogen
transgenic mice [35]. In our study, the deficiency of
catalase accelerated the albuminuria and glomerular
sclerosis in the ADR nephropathy model. These data
suggest that reactive oxygen species may contribute to
progressive renal injury. Injac et al. reported that the
activity of catalase, which detoxifies hydrogen peroxide
to H2O, was increased after ADR administration in
rats [36]. We measured the catalase activity in the
whole kidneys of wild-type mice, and found that its
level increased after ADR administration. Therefore,
the differences in the albuminuria and the degree of
glomerulosclerosis between wild-type and acatalasemic
mice may be due to the significant difference of cata-
lase activity in kidneys in these mice and the inability
of the acatalasemic mice to increase catalase activity
under oxidative stress.
Sheerin et al. reported that ADR-injected mice that
died in the complement protein C3+/+ group at 6
weeks had a high serum urea level prior to death [37].
In the current study, all mice survived for at least 4
weeks after the injection of 15 mg/kg BW ADR; how-
ever 44.7% of the acatalasemic mice and 40.8% of the
wild-type mice died 8 weeks after the administration of
ADR. These mortality rates were not significantly differ-
ent between the two groups (Additional file 1: Figure
S1B). Since the incidence of albuminuria was analyzed
in all of the mice that had survived at 8 weeks, but his-
tological studies were not performed in more than half
of the mice that survived at 8 weeks, bias might have
been introduced into the analysis. We did not take
blood samples or evaluate the serum urea levels in
ADR-treated mice that died just before the end of the 8
w e e k si nt h i ss t u d y .I na d d i t ion, the administration of
ADR can cause cardiotoxicity [15] and gastrointestinal
toxicity in mice [38], however we could not confirm
these toxicities in our experiments.
Acatalasemia is a rare human disease [3,39]. It is
unknown whether albuminuria and glomerulosclerosis
are related to low catalase activity in humans, although
the total antioxidant capacity is correlated with albumi-
nemia, and inversely correlated with proteinuria and
anti-DNA antibodies in subjects with lupus nephritis
[40]. In addition, apoptosis, which is thought to be
related to oxidative stress, correlated with the immuno-
serological activities of lupus nephritis [41] and idio-
pathic early FSGS [42]. However, the mechanism(s) by
which oxidative stress influences human renal disease is
largely unknown. Further studies are needed to elucidate
whether and how a low catalase activity in humans
Figure 5 The renal catalase activities in wild-type (open bars)
and acatalasemic mice (closed bars). Each column consists of the
means ± SE. N = 5 to 10 animals/group. *: P < 0.05 vs. wild-type
adriamycin (ADR) mice at the same time point. **: P < 0.01 vs. wild-
type ADR mice at the same time point. ##: p < 0.01 vs. week 0 in
the same group.
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ciated with kidney diseases.
Conclusions
We herein demonstrated that ADR induced more albu-
minuria and glomerulosclerosis in catalase-deficient
mice. Treatment with catalase supplementation may
contribute to the suppression of progressive renal injury
with proteinuria and glomerulosclerosis.
Additional material
Additional file 1: Figure S1 The survival rate in the wild-type (open
square) or acatalasemic mice (closed square) used for the
adriamycin nephropathy model.( A) The mice treated with a dose of
10 mg/kg BW (N = 24, in each group). (B) The mice treated with a dose
of 15 mg/kg BW (N = 46 to 66 animals/group). P = 0.56. (C) The mice
treated with a dose of 20 mg/kg BW (N = 3, in each group). P = 0.43. n.
s., not significant.
Additional file 2: Table S1 Primers used for direct sequencing.
Additional file 3: Figure S2 Electron micrographs of wild-type (A, C
and E) and acatalasemic (B, D and F) kidneys are shown. The
glomeruli 8 weeks after treatment with the vehicle control showed
almost normal foot processes (A and B). Note the increased podocyte
foot process effacement of both kidneys (arrowheads in C through F)a t
4 (C and D) and 8 (E and F) weeks after adriamycin administration. The
effacement score of the podocytes (G) of wild-type (open bars) or
acatalasemic (closed bars) mice are also shown. Scale bars: 1.0 μm. Each
column shows the means ± SE. N = 5 to 6 glomeruli/group. ##: p < 0.01
vs. vehicle control at 8 weeks in the same group.
Additional file 4: Figure S3 The results of the toll-like receptor-4
gene (Tlr4) mutation analysis in exon 3 in wild-type (C3H/
AnLCsaCsa) and acatalasemic mice (C3H/AnLCsbCsb). (A) A diagram
of exon 3 along with primer designs for PCR and the sequences. (B) The
results of the sequence analysis. Tlr4 does not show the missense
mutation, a C to A transversion (Pro712His), which was reported in the
C3H/HeJ mice strain.
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